Preclinical animal studies showed that anti-sclerostin antibodies induce new bone formation in bones infiltrated with myeloma or breast cancer cells, increase bone mass, and improve bone mechanical properties [100,101,102,103,104,106,108]. This evidence concerns the gene SOST and plasma cell myeloma.